Volitionrx LTD Form 4 insider transactions

Cameron John Reynolds, CEO of VolitionRx, amended his stock options on January 29, 2025, involving the cancellation of old options and the grant of replacement options.

Director Guy Archibald Innes amends stock options at VolitionRx, resulting in the cancellation of old options and the grant of replacement options.

Jasmine Kway, CEO Singapore Volition, amended stock options, resulting in the cancellation of old options and the grant of replacement options.

Rodney Gerard Rootsaert, Secretary of VolitionRX Ltd, received amended stock options on January 29, 2025, effectively replacing previously granted options.

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, amended his stock options, effectively replacing older options with new ones that have a later expiration date.

Ann-Louise Batchelor, Group Chief Marketing Officer at VolitionRx, amended her stock options, effectively replacing older options with new ones.

Director Guy Archibald Innes of VolitionRx Ltd. was granted 50,000 restricted stock units, according to a recent SEC filing.

VolitionRx director Guy Archibald Innes acquired 174,764 shares of common stock at $0.5722 per share through a registered direct offering.

Director Timothy Still acquired 87,382 shares of VolitionRx common stock at $0.5722 per share through a registered direct offering.

VolitionRx's Chief Scientific Officer, Jacob Vincent Micallef, acquired 43,691 shares of common stock at $0.5722 per share through a registered direct offering.

VolitionRx CEO Cameron Reynolds acquired 139,811 shares of common stock at $0.5722 per share through a registered direct offering.

Rodney Gerard Rootsaert, a Secretary at VolitionRx Ltd., received 7,302 restricted stock units in lieu of cash compensation.

VolitionRx Limited's General Counsel has been awarded 11,527 restricted stock units in place of cash compensation, according to a recent SEC Form 4 filing.

Director Guy Archibald Innes of VolitionRx Ltd. received 17,296 restricted stock units in lieu of cash compensation, according to a recent SEC filing.

Gael Forterre, Chief Commercial Officer of VolitionRx, received 4,828 restricted stock units in lieu of cash compensation.

Director Ethel Rubin of VolitionRx Ltd. received 8,648 restricted stock units (RSUs) in lieu of cash compensation, vesting over several dates.

Jasmine Kway, CEO of VolitionRx Singapore, received 15,169 restricted stock units in lieu of cash compensation.

Director Alan Colman of VolitionRx Ltd. was granted 12,972 restricted stock units (RSUs) in lieu of cash compensation.

Ann-Louise Batchelor, Group Chief Marketing Officer at VolitionRx, received 13,143 restricted stock units in lieu of cash compensation.

Director Kim Nguyen of VolitionRx Ltd. was awarded 8,648 restricted stock units in lieu of cash compensation, according to a recent SEC filing.

VolitionRx's Chief Financial Officer, Terig Hughes, received 12,683 restricted stock units (RSUs) in lieu of cash compensation, vesting over several dates.

VolitionRx's Chief Medical Officer, Andrew Retter, received 9,365 restricted stock units (RSUs) in lieu of cash compensation.

VolitionRx CEO, Salvatore Thomas Butera, received 16,871 restricted stock units and disposed of 99,350 common shares.

Director Timothy Still receives 1.4 million restricted stock units from VolitionRX, with vesting conditions tied to time and stock price performance.

CEO Salvatore Butera disposed of 5,834 VolitionRx shares to cover tax obligations related to the settlement of restricted stock units, while retaining 276,719 shares.

Ann-Louise Batchelor, Group Chief Marketing Officer at VolitionRx, reports a transaction involving the withholding of shares to cover tax obligations upon the settlement of restricted stock units.

Rodney Gerard Rootsaert, Secretary of VolitionRx, reports the retention of shares by the company to cover tax obligations related to restricted stock units.

Gael Forterre, Chief Commercial Officer of VolitionRx, reports a transaction involving the withholding of shares to cover tax obligations related to restricted stock units.

Nicholas Plummer, GC of Volition Diagnostics, reports the cancellation of 8,146 common stock shares to cover tax obligations related to restricted stock units.

Jacob Vincent Micallef, Chief Scientific Officer of VolitionRx, reports a transaction involving the withholding of shares to cover tax obligations upon the settlement of restricted stock units.